JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Strona główna・Stock List・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Closed

SectorHealthcare

107.28 -0.45

Buy Sell

Overview

Share price change

24h

Current

Min

103.51

Max

108.02

Key metrics
By Trading Economics
Income	-6.3M -53M
Sales	2.8M 51M
EPS	-0.82
Profit margin	-103.131
Employees	283
EBITDA	-7.6M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+30.64% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	-281M 7.3B
Previous open	107.73
Previous close	107.28

News Sentiment

By Acuity

50%

152 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

60 / 65.58 Support & Resistance

Rhythm Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lut 2026, 23:11 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 lut 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 lut 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 lut 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 lut 2026, 23:38 UTC

Earnings

AMD Sales Climb on Help From Data-Center Business -- Update

3 lut 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 lut 2026, 23:27 UTC

Acquisitions, Mergers, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 lut 2026, 23:25 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 lut 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 lut 2026, 23:22 UTC

Acquisitions, Mergers, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 lut 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 lut 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 lut 2026, 22:56 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 lut 2026, 22:40 UTC

Earnings

Amdocs Extends Collaboration With T-Mobile

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Adj EPS $1.81

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Rev $1.16B

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q EPS $1.45 >

3 lut 2026, 22:38 UTC

Earnings

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 lut 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 lut 2026, 22:14 UTC

Earnings

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 lut 2026, 22:13 UTC

Earnings

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 lut 2026, 22:12 UTC

Earnings

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 lut 2026, 22:10 UTC

Earnings

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 lut 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Comparison

Price change

Rhythm Pharmaceuticals Inc Forecast

Price Target

By TipRanks

30.64% upside

12 Months Forecast

Average 142.38 USD 30.64%

High 167 USD

Low 125 USD

Based on 15 Wall Street analysts offering 12 month price targets forRhythm Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Rhythm Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

60 / 65.58Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

152 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.